Physician profile
Douglas K Devries
NPI 1629037296
$1,282,708.16
in general payments reported to CMS, 2019-2025
40 companies · $291K in 2025
The $291K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200K · 2020: $115K · 2021: $114K · 2022: $207K · 2023: $181K · 2024: $175K · 2025: $291K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $202K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $193K · Consulting Fee: $122K · Travel and Lodging: $95K · Food and Beverage: $20K · Honoraria: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $201,877.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $192,800.00 |
| Consulting Fee | $121,587.50 |
| Travel and Lodging | $95,303.27 |
| Food and Beverage | $19,502.81 |
| Honoraria | $15,425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $177,387.22 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $174,431.00 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Dompe US, INC. | $129,598.50 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $125,641.69 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $94,551.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $81,702.28 | 2019-2023 | Xiidra |
| Oyster Point Pharma, INC. | $80,668.75 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $78,607.21 | 2019-2025 | Tryptyr, Eysuvis, Precision 7 |
| Johnson & Johnson Surgical Vision, INC. | $52,236.12 | 2019-2022 | |
| Lumenis Be INC | $42,246.62 | 2021-2025 | Optilight |
| Lumenis, INC | $37,609.76 | 2019-2021 | |
| Shire North American Group INC | $35,407.69 | 2019 | |
| Kala Pharmaceuticals, INC. | $24,350.26 | 2019-2021 | |
| Sight Sciences, INC. | $24,031.70 | 2019-2024 | Tearcare System |
| Alcon Research LLC | $22,544.73 | 2019-2025 | Tryptyr |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $20,835.97 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $18,637.28 | 2022-2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17,260.65 | 2019-2021 | |
| Harrow Eye, LLC | $9,347.78 | 2025 | Vevye |
| Tearlab Corp | $8,610.45 | 2019-2023 | Tearlab Osmolarity System |
| Thea Pharma INC. | $7,496.82 | 2022 | |
| Abbvie INC. | $5,480.24 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $3,780.26 | 2019-2022 | |
| Rxsight INC | $3,069.11 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Quidel Corporation | $1,630.05 | 2021 | |
| Beaver-Visitec International, INC. | $1,500.00 | 2019 | |
| Nordic Pharma, INC. | $1,400.00 | 2025 | Lacrifill |
| Mallinckrodt Hospital Products INC. | $1,256.51 | 2021-2025 | Acthar |
| Eyepoint US, INC. | $854.00 | 2019 | |
| Ortho-Clinical Diagnostics, INC. | $110.07 | 2024 | |
| Omeros Corporation | $93.87 | 2019 | |
| Maculogix, INC. | $88.12 | 2019 | |
| Ivantis, INC | $68.00 | 2019 | |
| Coopervision INC. | $54.35 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $28.82 | 2019 | |
| Immunogen, INC. | $26.01 | 2023 | Elahere |
| Aerie Pharmaceuticals, INC. | $24.78 | 2021 | |
| Amgen INC. | $21.98 | 2025 | Tepezza |
| Alimera Sciences, INC. | $18.21 | 2024 | Yutiq, Iluvien |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,049,162.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.